Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MM-398 Clear all
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 10, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

NCT05049863
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Mycophenolate Mofetil, Allopurinol, Irinotecan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT02551991
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
29
States / cities
Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

NCT05854498
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Liposomal irinotecan, TAS102, Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Palo Alto, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

NCT00364143
View directory record Official record
Conditions
Cancer
Interventions
IHL-305 (irinotecan liposome injection)
Drug
Lead sponsor
Yakult Honsha Co., LTD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

NCT04150640
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
Nal-IRI, Oxaliplatin, 5-FU, Trastuzumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

NCT07076212
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil, Leucovorin, Gemcitabine (mg/m²), Nab-paclitaxel, Cisplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

NCT03088813
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan liposome injection, Topotecan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559
View directory record Official record
Conditions
Solid Tumor
Interventions
Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

NCT01494506
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
MM-398, 5 Fluorouracil, Leucovorin
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
23
States / cities
Gilbert, Arizona • Glendale, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

NCT06835387
View directory record Official record
Conditions
Small Bowel Adenocarcinoma
Interventions
Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin
Drug
Lead sponsor
Tiago Biachi de Castria
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Not listed Phase 1 Interventional

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

NCT03703063
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04752696
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Onvansertib, Nanoliposomal irinotecan, Leucovorin, Fluorouracil
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Folfox+Irinotecan+Chemort In Esophageal Cancer

NCT04656041
View directory record Official record
Conditions
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Interventions
FOLFOX/ nal-IRI, Paclitaxel, Carboplatin, Proton Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

NCT04005339
View directory record Official record
Conditions
Advanced Biliary Tract Cancer
Interventions
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 10, 2026, 5:48 AM EDT
Not yet recruiting Phase 1 Interventional

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

NCT07060014
View directory record Official record
Conditions
Advanced Small Intestine Cancer, Appendiceal Cancers
Interventions
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 10, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Phase I Trial HIPEC With Nal-irinotecan

NCT04088786
View directory record Official record
Conditions
Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
Interventions
nanoliposomal irinotecan
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lexington, Kentucky • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 10, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

NCT06821997
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Sucrosofate, Leucovorin Calcium, Oxaliplatin, Surgical Procedure
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 10, 2026, 5:48 AM EDT